We are live on ! Find out more
SC

Sophrosyne Capital Portfolio holdings

AUM $11.5M
1-Year Est. Return 17.82%
This Fund
S&P 500
This Quarter Est. Return
+4.25%
1 Year Est. Return
+17.82%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$13.4M
AUM Growth
-$44.9M
Cap. Flow
-$45.1M
Cap. Flow %
-337.36%
Top 10 Hldgs %
98.59%
Holding
35
New
1
Increased
Reduced
13
Closed
20

Top Buys

Rank Stock Value
1
GMO
General Moly, Inc.
GMO
+$11.4K

Sector Composition

Rank Sector Weight
1 Healthcare 48.11%
2 Utilities 29.4%
3 Communication Services 8.27%
4 Financials 7.81%
5 Miscellaneous 3.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SHOR
26
DELISTED
ShoreTel, Inc.
SHOR
-202,828
Closed -$1.38M
ZLTQ
27
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
-146,097
Closed -$4.51M
TNGO
28
DELISTED
Tangoe, Inc.
TNGO
-18,100
Closed -$250K
RNF
29
DELISTED
RENTECH NITROGEN PARTNERS, L.P. INT
RNF
-131,900
Closed -$1.99M
RVLT
30
DELISTED
Revolution Lighting Technologies, Inc. - Class A
RVLT
-7,414
Closed -$82K
CYNI
31
DELISTED
CYAN INC COM
CYNI
-180,500
Closed -$720K
CKSW
32
DELISTED
CLICKSOFTWARE TECH LTD
CKSW
-85,400
Closed -$749K
PKT
33
DELISTED
PROCERA NETWORKS INC NEW COM STK (DE)
PKT
-226,806
Closed -$2.13M
BDSI
34
DELISTED
BioDelivery Sciences International, Inc.
BDSI
-87,119
Closed -$913K
RTK
35
DELISTED
Rentech, Inc.
RTK
-161,200
Closed -$1.81M

Similar funds

Sophrosyne Capital's Q2 2015 Portfolio in Review

As of Q2 2015, Sophrosyne Capital held 35 positions worth $13.4M, down 77% from $58.3M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Sophrosyne Capital withdrew a net $45.1M in Q2 2015, closing 20 positions and reducing 13 holdings. Its most notable exit was ZELTIQ Aesthetics, Inc., an estimated $4.51M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 48% of assets, up from 37% a quarter earlier, followed by Utilities and Communication Services.

Against the trend, Sophrosyne Capital opened a new position in General Moly, Inc. worth $11K.

  • Sophrosyne Capital's largest Q2 2015 buy was General Moly, Inc.: 16,000 shares worth $11K.
  • Sophrosyne Capital's biggest Q2 2015 reduction was iRadimed, cutting an estimated $4.94M.
  • Sophrosyne Capital fully exited ZELTIQ Aesthetics, Inc. in Q2 2015, selling an estimated $4.51M.
  • Sophrosyne Capital's ten largest holdings make up 99% of its $13.4M portfolio in Q2 2015.
  • Sophrosyne Capital opened 1 new position and closed 20 in Q2 2015.
  • Sophrosyne Capital's portfolio value fell 77% quarter-over-quarter to $13.4M.

Based on Sophrosyne Capital's 13F filing for Q2 2015, filed 14 Aug 2015.